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	 m i n i r e v i e wIn 2004, three groups reported somatic mutations in the EGFR 
gene in non-small cell lung cancer (NSCLC) (Lynch et al., 2004; 
Paez et al., 2004; Pao et al., 2004). The mutations are either 
short, in-frame deletions or insertions or substitutions clustered 
around the region encoding the ATP binding pocket of the recep-
tor’s tyrosine kinase domain in exons 18–21. The majority of 
patients with these tumors exhibit durable clinical responses to 
the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, 
suggesting that they are “gain-of-function” mutations that repre-
sent a functional marker of EGFR dependence in NSCLC. The 
two most common mutations are an in-frame deletion in exon 19, 
which eliminates a conserved LREA motif, and an L858R substi-
tution in exon 21 (Shigematsu et al., 2005). Two groups have now 
reported results with mouse transgenic models expressing these 
mutations (Ji et al., 2006 [this issue of Cancer Cell ]; Politi et al., 
2006). Expression of the EGFR mutants 
was targeted to lung type II alveolar cells 
by crossing mice carrying Clara cell secre-
tory protein (CCSP)-regulated reverse tet-
racycline transactivator (rtTA) transgene 
with mice carrying either L585R/EGFR 
or EGFR with deleted LREA (Del/EGFR) 
transgene regulated by tetracycline 
(tet)-responsive elements. This allowed 
for the generation of bitransgenic mice 
(CCSP/rtTA × tet-op/L858R hEGFR and 
CCSP/rtTA × tet-op/Del hEGFR) in which 
administration of doxycycline resulted in 
the expression of mutant human EGFR 
in lung pneumocytes.
Administration of doxycycline led to tis-
sue-specific expression of the transgenes 
and, within a few weeks, the development 
of focal or diffuse bronchioloalveolar car-
cinoma (BAC), in some cases preceded 
by precancerous adenomatous lesions. 
Upon longer transgene induction (>4 
weeks), mice developed invasive ade-
nocarcinomas. Doxycycline withdrawal 
resulted in complete regression of lung 
cancers with no recurrences observed 
during the withdrawal period, although the 
follow-up was short. Treatment with the 
EGFR TKI erlotinib caused rapid regres-
sion of doxycycline-treated tumors as well 
as inhibition of EGFR phosphorylation 
and postreceptor signal transducers. It 
remains to be determined if tumors recur 
after prolonged deinduction or longer therapy with erlotinib and 
whether they remain EGFR dependent at the time of relapse. If 
erlotinib was not as effective in providing long-term tumor control 
compared to doxycycline withdrawal, this would suggest that the 
small molecule inhibitor did not achieve complete and prolonged 
inactivation of the mutant kinase. In the paper by Ji et al., treat-
ment with the irreversible covalent inhibitor HKI-272 and more 
prolonged therapy (>2 weeks) with the EGFR monoclonal anti-
body cetuximab also resulted in tumor regression.
These results in genetically engineered mice confirm that 
L8558R/EGFR and Del/EGFR are dominant oncogenes that 
alone can catalyze the whole process of cancer development. 
The histological changes induced by expression of the mutant 
transgenes represent a progressive spectrum of lesions similar 
to the one observed in patients with NSCLC harboring these 
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Figure 1. Transgenic mice expressing l858r/eGFr and Del/eGFr develop bronchioloalveolar cancer 
and lung adenocarcinoma
These histological types of tumors are identical to those observed in patients with nsclc harboring 
these same receptor mutants. Mouse lung tumors responded dramatically to treatment with erlotinib, 
HKi-272, or cetuximab. clinical activity of HKi-272 and cetuximab against human nsclc expressing eGFr 
mutations remains to be formally tested. A comparative of gene profiles between mouse and human 
lung cancers expressing eGFr mutations has not been reported yet.cancer cell 9, June 2006 ©2006 elsevier inc. 421
	 m i n i r e v i e wmutations. Interestingly, in most primary tumors, BAC is associ-
ated with a component of invasive adenocarcinoma similar to the 
tumor histologies observed by Ji et al. and Politi et al. Further, 
adenocarcinomas with BAC features are more responsive to the 
EGFR TKI gefitinib and may have a higher frequency of EGFR 
mutations than pure adenocarcinomas or pure BAC (Miller et al., 
2004, 2006).
The marked reduction and/or elimination of lung cancers upon 
either doxycycline removal or treatment with the EGFR TKIs clearly 
suggests that lung tumorigenesis is specific to the EGFR muta-
tions. The high efficacy of the covalent inhibitor HKI-272, which has 
activity against erlotinib- and gefitinib-insensitive EGFR mutants 
(Kwak et al., 2005), supports the possibility of using it in com-
bination with erlotinib as first line therapy in order to reduce the 
likelihood of therapeutic resistance. The effect of cetuximab, an 
antibody that binds a conserved region in the ectodomain of human 
EGFR but not mouse EGFR (Goldstein et al., 1995) and thus is 
unlikely to exert off-target effects in mice, also supports transgene 
specificity. Interestingly, the effects of the antibody appeared to be 
independent of blockade of ligand binding, suggesting an alterna-
tive mechanism of action that perhaps can be exploited in combi-
nation with EGFR TKIs. Considering that the mice in this study are 
fully immunocompetent, antibody-dependent, cell-mediated cyto-
toxicity (ADCC) (Modjtahedi et al., 1994; Sampson et al., 2000) is 
a possible mechanism of cetuximab action.
Additional benefits from the temporally regulated models 
generated by Politi et al. and Ji et al. can be derived from their 
integration into the preclinical drug development process. For 
example, they can be used as “filters” where new EGFR inhibi-
tors, either alone or in combination with other drugs, are tested 
for target validation (as was done in these papers with P-EGFR 
and postreceptor transducers), pharmacokinetic properties, and 
in vivo efficacy (Figure 1). Obviously, lack of molecular and/or 
clinical activity over erlotinib or HKI-272 in the long run would 
suggest reexamination of the development of such agents or 
combinations. This is probably an unlikely scenario for single 
drugs in light of the agents already available for these types of 
NSCLC. Another use of these models could be the elucidation 
(and timing) of biochemical or molecular readouts predictive of 
tumor response. A pertinent example was recently contributed 
by Majumder et al. in a transgenic mouse model in which pros-
tate-specific expression of an activated allele of Akt resulted in 
prostatic intraepithelial neoplasia (PIN). Administration of a TOR 
inhibitor to these mice eradicated the PIN lesions and downregu-
lated mRNAs regulated by HIF-1α, among these genes encod-
ing enzymes regulatory of the glycolytic pathway (Majumder et 
al., 2004). Since these enzymes are responsible for uptake and 
retention of the positron emission tomography (PET) tracer [18F]2-
fluoro-2-deoxy-d-glucose (FDG), scanning with FDG-PET was 
proposed as a readout of TOR activation in tumors that can be 
used to monitor the efficacy of anti-TOR therapies with noninva-
sive methods. This question is being prospectively addressed in 
investigational clinical trials with TOR inhibitors.
Even though the majority of NSCLCs expressing EGFR muta-
tions in the kinase domain respond to EGFR TKIs, insertions in 
exon 20 exhibit resistance to gefitinib and erlotinib (Greulich et 
al., 2005). In addition, the majority of EGFR mutant NSCLCs that 
initially respond to EGFR inhibitors eventually escape therapy. 
A secondary mutation in exon 20 (T790M) was discovered in 
patients with a primary mutation that progressed after an initial 
response to gefitinib or erlotinib (Kobayashi et al., 2005; Pao et al., 422 2005a). Because of the presence of the bulkier methionine side 
chain in the ATP binding pocket, T790M sterically hinders binding 
erlotinib and gefitinib, explaining drug resistance (Kobayashi et 
al., 2005). Furthermore, mutations in the K-Ras gene are mutually 
exclusive with EGFR mutations (Kosaka et al., 2004; Shigematsu 
et al., 2005) and predict for lack of sensitivity to EGFR inhibi-
tors (Pao et al., 2005b). In most patients with NSCLC-containing 
EGFR mutations, the mechanisms of de novo or acquired resist-
ance to EGFR TKIs are unknown. The emergence of therapeutic 
resistance, especially after therapy with a single antioncogene 
drug, is not surprising though if we consider that potent onco-
genes, such as L858R/EGFR and Del/EGFR, induce sufficient 
cell expansion where additional compensatory or complementary 
mutations occur. Moreover, intrinsic pharmacological limitations 
(e.g., short half-life) may affect the ability of a single drug to com-
pletely disable amplified oncogenic networks, especially if the 
tumor burden is high.
Several reports suggest the possibility that conditional trans-
genic models may generate insights about secondary genetic 
alterations that eliminate the dependence on the original onco-
gene and thus potentially generate drug resistance. For exam-
ple, regulated overexpression of c-Myc in the mouse mammary 
gland results in invasive cancers. These tumors regress upon 
deinduction of c-Myc. Eventually, after a few cycles of c-Myc 
induction and deinduction, a large proportion of tumors did not 
regress when c-Myc was downregulated with the majority of these 
Myc-independent cancers expressing K-ras or N-ras mutations 
(D’Cruz et al., 2001). In another study, transgenic mice express-
ing tetracycline-regulated Neu oncogene in the mammary gland 
developed mammary cancers upon induction of Neu. Deinduced 
tumors eventually escaped Neu dependence, upregulated the 
transcriptional repressor Snail, and exhibited evidence of an 
epithelial-to-mesenchymal transition (EMT). Snail was sufficient 
to induce mammary tumor recurrence in vivo and EMT, and its 
overexpression in primary human tumors predicted poor patient 
outcome in patients with breast cancer (Moody et al., 2005). In 
this example using a conditional transgenic mouse model of 
breast cancer, the acquisition of a secondary genetic alteration 
upon escape from Neu dependence provided information about a 
molecular pathway that may identify tumors resistant to anti-Neu 
therapies and/or with a poor prognosis.
These elegant observations in genetically engineered mice 
have to be followed and validated in patients. It can also be 
argued that there is not a good correlation between mouse and 
human cancer, and therefore, the examples chosen represent 
spurious leads. However, the papers by Ji et al. and Politi et al. 
suggest that that may not be the case, as regulated induction of 
either L858R/EGFR or Del/EGFR in mouse lung pneumocytes 
was able to induce syndromes that phenocopy to a significant 
degree those observed in humans. Further, recent studies using 
hierarchical clustering analysis of RNA signatures in mouse and 
human tumors clearly indicate patterns of gene expression and 
genes that can be interrogated in preclinical studies (Ellwood-Yen 
et al., 2003; Lee et al., 2004; Sweet-Cordero et al., 2005). Similar 
comparisons between the mouse lung tumors and primary human 
cancers expressing EGFR mutations are now doable using the 
animal models discussed in this preview. At the end of the day, 
however, how we exploit mouse models for the study of cancer 
biologyas well as within a streamlined process of drug develop-
ment will depend on how open we are to exploring their utility and 
how inquisitive we want to be.cancer cell June 2006
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